Researchers are using targeted protein degradation as a strategy to develop drugs that target disease-causing proteins where traditional inhibitor drugs can’t be used.
In this infographic, we discuss both inhibition and degradation, the advantages and challenges related to each approach, and the key points you need to consider when designing your protein degraders.
Ready to tackle your challenging affinity screening?
Discover tools you can use
14:18Transcription factors have traditionally been considered challenging therapeutic targets. Their intrinsic disorder and lack of small molecule binding pockets make them intractable to small molecule ap
Drug Discovery Chemistry is an annual event that focuses solely on early drug discovery, where scientists from around the world gather to showcase their research and participate in thoughtful...
12:54Dianthus is a biophysical screening instrument that uses Spectral Shift technology to measure molecular interactions for hit ID, hit-to-lead, and lead optimization. It offers a 384-well plate format a
11:48MYC is an important therapeutic target that associates with MAX to regulate gene transcription. Its lack of binding pockets and the presence of disordered regions make it a difficult protein to study
16:42The development of your protein degrader is a multi-step and complex process usually packed with challenges that if left unsolved will delay the progress of your project. What if you could overcome co
22:23Chances are your company’s research and development pipeline includes several PROTAC candidates — placing you with many others in the race to bring successful and efficient protein degraders to the cl
37:25When you’re entrusted with developing therapeutics for challenging or undruggable targets, it’s a struggle to characterize molecular interactions. And it’s not for lack of effort or expertise — SPR an
NanoTemper Technologies, announced today the launch of Spectral Shift technology within their Dianthus instrument, built to handle the most challenging affinity-based screenings in drug discovery....
If you’re new to the world of TPD or you’re trying to keep up with all developments in this fast-moving field, here are some terms and definitions that will help you.
Use this downloadable list of 2023 Targeted Protein Degradation conferences to choose which one(s) to attend. Learn when and where they’ll happen, who’ll be there, and the main focus.
With so much interest and investment in target protein degradation, a lot can happen in a year. Here are 9 conferences to get up-to-date on recent progress and the latest approaches. You’ll not...
One advantage of PROTACs is their unique mode of action — the induced proximity of an E3 ligase and the protein of interest (POI) triggers the ubiquitination and then degradation of the POI by the...
